MitoSense

 Mitochondria Organelle Transplantation

MitoSense is a research and development company founded in 2019 that is focused on novel treatment approaches for mitochondria transplantation. They target diseases associated with mitochondrial dysfunction, such as currently uncurable neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), Parkinson's, and Alzheimer's. Their approach centers on Mitochondria Organelle Transplantation (MOT™), a patented technology for utilizing extracellular vesicles to transport healthy mitochondria from donor into diseased cells. MitoSense also entered into a collaboration on heart disease. By replenishing healthy mitochondria, MitoSense aims to improve energy production and potentially slow or reverse the progression of mitochondrial dysfunction-related diseases.